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Abstract
Intellectual disability is the most common developmental disorder characterized
by a congenital limitation in intellectual functioning and adaptive behavior. It
often co-occurs with other mental conditions like attention deficit/hyperactivity
disorder and autism spectrum disorder, and can be part of a malformation
syndrome that affects other organs. Considering the heterogeneity of its causes
(environmental and genetic), its frequency worldwide varies greatly. This
review focuses on known genes underlying (syndromic and non-syndromic)
intellectual disability, it provides a succinct analysis of their Gene Ontology, and
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Introduction
The advances in scientific technology related to gene sequenc-
ing and discovery in recent years, such as high-throughput whole 
genome sequencing (WGS) and single-cell sequencing, have led 
to an increasing number of studies aimed at finding new causative 
genes for human diseases.
Owing to the heterogeneity of clinical features and causative fac-
tors (both genetic and environmental), characterization of intellec-
tual disability (ID) has benefited from these advances, as shown 
by the significant increase of publications (Figure 1). As defined 
by the Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition (DSM-5), ID is characterized by significant limitations 
in intellectual functioning and adaptive behavior, which include 
conceptual, social, and practical skills, arising “prior to age 18” (but 
it would be fair to say “with a prenatal origin”). The disorder is con-
sidered chronic and often co-occurs with other mental conditions 
like depression, attention deficit/hyperactivity disorder, and autism 
spectrum disorder (ASD). Furthermore, ID is often part of a malfor-
mation syndrome that affects other organs and their functions.
ID is the most common developmental disorder; however, given the 
heterogeneity of its causes, estimates of its frequency worldwide are 
highly variable (reviewed by 1). The prevalence of ID also varies 
depending on the age of patients, as illustrated by two Australian 
surveys in which prevalence was 3.3/1000 if the age range of 20 to 
50 years was considered2 but increased to 14.3/1000 if the age range 
was lowered to 6 to 15 years3.
The purposes of this review are to update the list of known genes 
related to ID and to provide a brief bioinformatic analysis of their 
Gene Ontology (GO). Eventually, we propose the use of a relative 
expression ratio (“Brain ratio”) to prioritize new candidate genes 
for ID.
Nomenclature: mental retardation versus intellectual 
disability
Changes in nomenclature (i.e. how we name things and concepts) 
are particularly delicate in science, since consistency in terminol-
ogy allows more precise communication4. As discussed elsewhere5, 
“mental retardation” has recently been substituted by the new term 
ID, which in our opinion is less accurate since it does not refer to 
the developmental nature of the disease and it does not reflect the 
progress of mental acquisitions that could nonetheless be achieved 
but at a slower pace. That said, we should remember that ID is not 
the only term employed to indicate delayed acquisition of psycho-
motor milestones. In fact, “developmental delay” is the second 
most common term found in the Clinical Synopsis of OMIM 
(Online Mendelian Inheritance in Man) (after “mental retarda-
tion”) and is widely used by pediatricians6. Other more complex 
terms that have been proposed, such as “intellectual developmental 
disorder”, “neurodevelopmental disorder”, or “developmental cog-
nitive impairment”7, though certainly more accurate than ID, have 
not gained in popularity. However, all of these terms refer to the 
slower acquisition of psychomotor milestones, resulting in a sig-
nificant impairment of cognitive functions (a) and adaptive behav-
ior (b), obviously with an early onset (c), compared with peers. 
Figure 1. Bar graph illustrating the number of publications per year from 2007 to 2015 obtained with the PubMed search “(intellectual 
disability OR mental retardation) AND (next-generation sequencing OR exome sequencing)”.
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Cognitive abilities can be measured by using a panoply of 
psychological tests, including the Wechsler Intelligence Scale 
for Children, that have as the output a numerical value known as 
“intelligence quotient” (IQ).
It is worth remembering that the term “pervasive developmental 
disorder” (PDD) is often used by psychologists and psychiatrists 
to refer to a group of conditions characterized by altered develop-
ment of multiple basic functions, including socialization and com-
munication. In May 2013, the DSM-5 was released and the term 
PDD was abandoned and substituted by ASDs. Finally, the term 
“learning disability” is usually reserved for specific impairments, 
like dyslexia and dyscalculia, that are associated with a child’s 
academic underperformance but not with a lower IQ.
Nomenclature also reflects social trends and sensibilities that vary 
with time and according to the different cultural context. Social 
perception has become a decisive factor in changing nomencla-
ture: the term “mental retardation” is not considered politically 
correct any longer because of the pejorative term “retard” that is 
used to stigmatize affected individuals4. The community of parents 
and patients has indeed shown strong disagreement with the term 
“mental retardation”, leading to “Rosa’s law”, signed by President 
Obama on October 5, 2010. The new bill requires the federal gov-
ernment to replace the term “mental retardation” with ID in every 
context. Therefore, we will use the term ID in this article to refer to 
“mental retardation” from now on.
Environmental and genetic causes of intellectual 
disability
ID can be caused by a variety of environmental and genetic causes, 
often combined with each other8–12. As illustrated in Figure 2, most 
of these causes exert their effects already during prenatal life. As 
indicated in table 1 of Chiurazzi and Oostra13, the severity of the 
clinical presentation is loosely correlated with the causal factor, and 
gross chromosomal imbalances, perinatal asphyxia, prenatal infec-
tions, or vascular accidents are related to the most severe cases. 
Variable (and dose-related) effects result from maternal exposure to 
toxic substances during pregnancy (e.g. environmental chemicals, 
use of drugs, and alcohol abuse), maternal conditions such as diabe-
tes or phenylketonuria, and premature birth. Common (but prevent-
able) environmental causes of ID are iodine deficiency and mal-
nutrition (of both mother and child), affecting millions of people 
in “developing countries”. The frequency of these various factors 
varies greatly among different countries and depends on (maternal) 
lifestyle as well as health-care quality.
Mendelian causes of ID result in highly variable phenotypes rang-
ing from mild (IQ of 55–70) to moderate (IQ of 40–55), severe (IQ 
of 25–40), and profound (IQ of less than 25), depending on the 
Figure 2. Schematic representation of neurodevelopmental stages, related to genetic and environmental factors and their time 
window. *For genetic factors, the onset of symptoms or time of detection is shown. Modified from 79.
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gene or genes involved, the effects of the mutation (dosage changes, 
loss-of-function mutation, and gain-of-function mutations), and the 
function(s) of the altered protein(s).
Clinically, it is useful to distinguish syndromic from nonsyndro-
mic forms of ID, depending on the involvement of other organs 
and the presence (or absence) of malformations or a typical (facial) 
gestalt (or both). However, it is not uncommon to observe that some 
mutations in a given gene cause a syndrome but that other muta-
tions in the same gene lead to nonsyndromic or “pure” forms of ID. 
Comorbidity with autism, epilepsy, and neuromuscular deficits (e.g. 
ataxia, spastic paraplegia, sensory/motor neuropathy, and muscular 
dystrophy) is common for nonsyndromic ID.
Development of a functional brain depends on a precise and com-
plex sequence of neuronal and glial cell proliferation, migration, 
and maturation. Some ID syndromes are associated with gross 
brain malformations (e.g. holoprosencephaly, schizencephaly, 
porencephaly, hydrocephalus, agenesis of corpus callosum, and 
cerebellar hypoplasia) or with neuronal migration disorders 
(e.g. lissencephaly, micropolygyria, double cortex, and ventricular 
nodular heterotopia) that can be assessed by neuroimaging tech-
niques. However, even in the presence of a morphologically normal 
brain, neuronal connectivity could be altered by a dysfunction of 
the glia (e.g. disorders of myelination) or neuronal crosstalk might 
be altered at the synaptic level, either because of a reduced number 
of mature dendritic spines or because of inefficient (or excessive) 
synaptic transmission14. Finally, even if both neurons and glial 
cells are well positioned, connected, and working, they could be 
damaged by toxic compounds accumulating in metabolic disor-
ders (toxic neurodegeneration). A careful clinical evaluation of the 
patient(s), including reconstruction of personal and family history, 
possibly integrated by neuroimaging or neurophysiological tests or 
both, may provide essential clues to reach a diagnosis and identify 
a specific cause of ID6,15,16.
A special note must be made for the extensive overlap between 
causes (and pathogenic pathways) of ID and those of autism or 
ASDs, since many patients have both ID and compromised social 
interaction and communication and vice versa17–19. For example, 
more than 100 genes and 40 genomic loci associated with ASD 
had been reviewed by Betancur in 201120 and all of these were also 
involved in ID.
Counting conditions with intellectual disability using 
OMIM
Curated lists of genes involved in ID have been published by some 
groups. Gilissen et al.21 created two lists including 528 genes 
with a “confirmed” pathogenetic role and 628 “candidate” genes 
with mutations reported in fewer than five patients. Another com-
prehensive list (DDG2P) was prepared to assist the Deciphering 
Developmental Disorders Study22, including 925 “confirmed” 
developmental disorder genes up to November 201323. Yet another 
list of 565 genes associated with ID (253 “known” and 312 
“candidate”) has been reported by Grozeva et al.24, who used the 
two previous lists as a starting point.
We decided to obtain an independent gene list by using OMIM and 
the National Center for Biotechnology Information (NCBI) GENE 
databases. To identify most (if not all) conditions with ID, we 
searched for entries with either “mental retardation” or “develop-
mental delay”, “intellectual disability”, and “cognitive impairment” 
in the Clinical Synopsis. It is worth noting that, at least in OMIM, 
the term “mental retardation” is still the most common (followed 
by “developmental delay”) term found in the Clinical Synopsis of 
981 OMIM entries. Furthermore, only conditions for which at least 
one gene has been identified were included. This OMIM search 
resulted in 900 conditions (listed in Supplementary Table 1) and 
was performed by using the following search string:
((((mental retardation[Clinical Synopsis]) OR developmental 
delay[Clinical Synopsis]) OR intellectual disability[Clinical Syn-
opsis]) OR cognitive impairment[Clinical Synopsis]) AND “prefix 
pound”[Properties].
These 900 conditions include several “genomic disorders” (i.e. 
microdeletion/duplication conditions such as Williams, velo-cardio- 
facial, and Wolf-Hirschhorn) and even Down syndrome. It is known 
that a few syndromes associated with these recurrent submicro-
scopic chromosomal aberrations are actually due to the altered 
dosage of just one gene25–27. However, to obtain a list of single genes 
underlying ID, after transferring the 900 conditions from OMIM 
to the NCBI GENE database (Figure 3) and finding 897 items, we 
manually removed 79 entries without a precise chromosomal loca-
tion, including those corresponding to genomic disorders (that may 
be potentially due to more than one gene). This final list contains 818 
protein-coding genes and has been ordered either by map_location 
or by alphabetical order of gene symbol (see Supplementary Table 2). 
In both lists, removed items are indicated in red.
Mapping intellectual disability genes and enrichment 
on the X chromosome
We then used the Genome Decoration page at NCBI to map the 
identified genes on the human karyogram (Figure 4). Not surpris-
ingly, the density of ID genes is higher in G-negative bands that are 
typically richer in protein-coding genes. Figure 5 is derived from 
Supplementary Table 2 and counts the number and proportion of 
ID genes relative to all protein-coding genes for each individual 
chromosome. The X chromosome appears to be enriched for genes 
mutated in patients with ID, be they syndromic or not (10% of all 
protein-coding genes on the X compared with 4% of the genomic 
average). Actually, the total number of X-linked ID (XLID) genes is 
higher than that (86) shown in Figure 5: now (March 2016) the total 
number of XLID genes is more than 100 out of about 800 protein-
coding genes on the X chromosome28–30. XLID genes have been 
identified earlier than autosomal ID genes because of their inher-
itance pattern that allows transmission through several unaffected 
carrier females, and they may explain part of the reported excess of 
male patients with ID31,32. However, is this enrichment real or sim-
ply due to ascertainment bias, since the identification of X-linked 
families is easier? Twenty-five years after the cloning of the first 
XLMR gene (FMR1, inactivated in the fragile X syndrome), we still 
do not have a definitive answer to this question and we may have 
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Figure 3. Counts of the major terms describing impaired development of cognitive functions in OMIM. The largest number indicated in 
black on the upper left of each term is the total number of counts without any limits, whereas the number of entries with the term specified in 
the Clinical Synopsis is indicated in blue on the lower left. To the right of each term are the counts of entries containing the term linked to at 
least one gene (upper right with a pound prefix [#], in black) and all entries containing the term in their Clinical Synopsis AND being linked to 
at least one gene (lower right with a pound prefix [#], in red). OMIM, Online Mendelian Inheritance in Man.
to wait until all ID genes have been identified to settle the dispute. 
However, several authors suggested the possibility that “intelligence 
genes” actually concentrated on the X chromosome because of a 
selective advantage in males32–34; this evolutionary effect would also 
explain why intelligence scores appear to be more variable in males 
compared with females (i.e. males tend to be over-represented at 
both ends of the general intelligence overall distribution)35.
Over the years, we and others have kept track of XLID conditions 
and genes29,36–39, and both sequencing40,41 as well as microdeletion/
duplication searches42 have been used to identify genetic determi-
nants of XLID. More genes are still being identified with exome 
sequencing of informative families30.
On the other hand, many syndromes with ID have been linked to auto-
somal loci, and in recent years a quest for ID genes on the autosomes 
has progressed rapidly. Recessive forms of both syndromic and 
“pure” ID have been identified thanks to the study of large consan-
guineous families coming from non-European countries like Iran43,44. 
However, large recessive pedigrees are rare, whereas many sporadic 
cases are observed among children of non-consanguineous parents, 
suggesting an autosomal dominant de novo origin45,46. These cases 
can be diagnosed by using next-generation sequencing (NGS) 
analysis techniques47 that have become available at more affordable 
prices in recent years.
Depending on the clinical signs and after an initial screening for 
fragile X syndrome (mostly with polymerase chain reaction [PCR]-
based techniques) and for copy number variants (CNVs), usually 
with array comparative genomic hybridization (array-CGH), many 
patients will hopefully receive a diagnosis thanks to NGS using 
resequencing gene panels, whole exome sequencing (WES), or 
WGS. Resequencing panels with tens or even hundreds of genes 
are very useful to screen large cohorts of patients in a cost-effective 
way and with sufficient confidence to write a report. For example, 
a diagnostic NGS test screening 99 X-linked and 118 autosomal 
genes48 has identified a causative mutation in 25% of 96 male 
and 10 female patients with ID (who had previously tested nega-
tive for fragile X and had a normal array-CGH). If WES or WGS 
is employed and a de novo mutation is suspected, it is useful to 
analyze the proband-parents trio in order to reduce the number 
of variants. Finally, a note of caution should be made about the 
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Figure 4. Mapping of the intellectual disability genes on the human karyogram (G-banded) using the Genome Decoration page at 
National Center for Biotechnology Information. See website at http://www.ncbi.nlm.nih.gov/genome/tools/gdp. Please note that genes 
causing ID tend to concentrate in G-negative bands, like all other genes. CI, cognitive impairment; DD, developmental delay; ID, intellectual 
disability; MR, mental retardation.
interpretation of rare variants: even a de novo loss-of-function muta-
tion should not be automatically considered pathogenic, as pointed 
out by Piton et al.29 for some XLID genes.
Gene Ontology analysis of intellectual disability genes
To provide an overview of the functions of the proteins encoded 
by genes listed in Supplementary Table 2, we performed a GO 
analysis using the free tool DAVID (Database for Annotation, 
Visualization, and Integrated Discovery) 6.7 (https://david.ncifcrf.
gov/)49. We analyzed the 818 official gene symbols with the 
following DAVID tools: functional clustering, functional annota-
tion, and functional table. To perform the analysis, we selected 
only the three main GO categories: Biological Process (BP_all), 
Molecular Function (MF_all), and Cellular Component (CC_all). 
We used medium stringency and default settings for the analysis, 
selecting Homo sapiens as the background species.
Of the 818 gene symbols, 774 (95%) were present in the DAVID 
GO dataset. Unmapped IDs are listed in Supplementary Table 3a. 
The three DAVID functionalities summarize the results in different 
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Figure 5. Distribution of intellectual disability genes per chromosome and comparison with the total amount of protein-coding and 
non-coding genes located on each chromosome. longnc, long non-coding; Mb, megabase; miscnc, miscellaneous non-coding; MR/ID, 
known mental retardation/intellectual disability genes; shortnc, short non-coding.
ways, providing a clustering of the GO terms on the basis of fold 
enrichment and relationships among ontology terms (functional 
clustering; see Supplementary Table 3b) or providing statistics of 
the ontology terms present in the results (functional annotation; see 
Supplementary Table 3c). The functional chart (see Supplemen-
tary Table 3d) reports the GO description for each gene present in 
the input list. We used functional clustering to highlight the over- 
represented GO terms, using an arbitrary fold enrichment cutoff 
of 10.00 (see Supplementary Table 3e). These clusters show an 
enrichment of cellular organelle (mainly mitochondria) assembly 
and functions.
GO results, by definition, are redundant and thus can be difficult to 
visualize. In fact, GO vocabularies are created as acyclic graphs, in 
which each term follows a hierarchical structure and has a “parent 
term” and a “child term”, and the complexity is increased by the 
fact that each term is allowed to have multiple parent and child 
terms. This confers multiple levels of interpretation to the GO anal-
ysis, although the increasing number of parent/child terms does not 
always add useful information50,51. To overcome this issue, DAVID 
functional annotation results, together with their relative p values 
and fold enrichment values (see Supplementary Table 3f), were 
further used for REViGO (Reduce + Visualize Gene Ontology) 
analysis (http://revigo.irb.hr/)52. All terms were included, using the 
following parameters: allowed similarity = 0.5 (small); first values 
provided = p values; database with GO term sizes = Homo sapiens; 
semantic similarity measure = SimRel. We decided to use the 
tree view for each main category (Biological Process, Cellular 
Component, and Molecular Function). Figure 6 shows the two 
graphs obtained with REViGO summarizing the over-represented 
(a) Biological Process or (b) Cellular Component GO terms 
associated with the 818 ID genes. These pictures underline that 
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Figure 6. REViGO tree analysis of over-represented Gene Ontology terms obtained with DAVID and associated with the 818 intellectual 
disability genes. Panel (a) shows Biological Process terms and panel (b) shows Cellular Component terms. DAVID, Database for Annotation, 
Visualization, and Integrated Discovery; REViGO, Reduce + Visualize Gene Ontology.
b
a
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multiple essential metabolic pathways, especially those related to 
energy production, are highly associated with the 818 ID genes (a). 
Also, the Cellular Component GO terms are diversified (b), and 
mitochondria are well represented.
Finally, we evaluated the 818 ID gene list with g:Profiler53,54, another 
useful GO annotation tool (http://biit.cs.ut.ee/gprofiler/), which scans 
not only GO terms but also other datasets like the Human Phenotype 
Ontology project55. Results obtained with g:Profiler are reported 
in detail in Supplementary Table 4 and confirm the variety of cel-
lular components involved in ID pathogenesis, and mitochondria 
again show up in the list (see Supplementary Table 4c), and among 
the top GO Biological Processes are “(central) nervous system 
development” and “neurogenesis” (see Supplementary Table 4b). 
Interestingly, when the Human Phenotype Ontology terms are 
examined (see Supplementary Table 4e), the first two terms of the 
list (with a highly significant p value of 9.61 × 10-297) are “Neurode-
velopmental abnormality” and “Intellectual disability”, followed by 
“Abnormality of nervous system physiology” (p value: 7.36 × 10-169) 
and “Neurodevelopmental delay” (p value: 9.14 × 10-143).
Identification of (new) intellectual disability genes
Several strategies have been employed to identify ID genes over 
the years. A thorough clinical examination of the proband(s) and 
the reconstruction of the family history are mandatory15 before any 
attempt is made to pinpoint the responsible gene. In fact, understand-
ing the genetic context (sporadic/familial and dominant/recessive) 
and collecting all clinical evidence (“diagnostic handles”) facilitate 
reaching a diagnosis. Furthermore, fragile X syndrome should be 
excluded by using the available PCR-based tests, considering the 
frequency of this condition and the dynamic nature of most muta-
tions in the FMR1 gene56, and array-CGH should be performed as a 
first-tier test to detect or exclude the presence of potentially relevant 
CNVs57. It is important to remember that if a CNV is detected, not 
only is the gene content of the deleted/duplicated region important 
but also the potential “position effects” (due to deletion or displace-
ment of enhancers) are extremely relevant58–60. However, even if 
array-CGH results were normal, a standard karyotype and confirm-
atory fluorescence in situ hybridization (FISH) analysis would still 
be necessary if a balanced translocation/inversion is suspected.
Then, if clinical examination and the first-tier tests (fragile X and 
array-CGH) are normal and balanced chromosomal aberrations have 
been excluded, direct searching for single-nucleotide variants 
(SNVs) or small insertions/deletions (indels) may be performed 
by using NGS techniques. Depending on the available resources, 
including bioinformatic support, either a large panel of known or 
candidate ID genes can be screened (as shown by 48) or the (cur-
rently known) human exome (WES) or genome (WGS) could be 
investigated. These latter approaches can potentially identify 
“new genes” responsible for ID, although the number of variants 
identified in each patient is challenging and not always easily 
interpreted41. The availability of at least the patient’s parents (trio 
analysis) facilitates variant interpretation45, and many laboratories 
prefer to invest the extra resources in order to increase the chances 
of reaching a diagnosis.
When examining the results of any WES/WGS experiment, 
known disease genes (e.g. OMIM genes) should be examined first 
if mutations are identified in any of them, even if the phenotype 
of proband(s) does not correspond to that already reported in the 
literature, since phenotypic heterogeneity is common in human 
genetics. Furthermore, SNV or indels identified in regulatory and 
untranscribed or untranslated regions of a specific ID gene could 
eventually be linked to abnormal transcript levels that cause the 
disease phenotype, as was found to occur in the X-linked HCFC1 
gene61; however, such sequence changes are extremely difficult to 
detect since they do not fall in the open reading frame and their effect 
might be appreciated only if mRNA levels were quantitated62. 
In any case, a (long) list of potentially causative variants in several 
genes is the typical result of WES/WGS experiments and there-
fore prioritization of candidate variants (based on the presumed 
effect on the encoded protein)63 is very important to identify the 
(new) causative ID genes64. Gene prioritization establishes a rank-
ing of candidate genes on the basis of their relevance to the bio-
logical process of interest: this is a critical process since the “real” 
causative gene might be excluded from further analysis depend-
ing on the criteria chosen by the researcher. Several computational 
approaches have been developed for selecting disease candidate 
genes65,66 on the basis of either functional (what they do) or topo-
logical (where they do it) similarity to known disease genes.
In the postgenomic era, when large sets of data are available on the 
majority of human genes, numerous correlations can be established 
to connect genes in networks on the basis of their sequence similar-
ity (paralogues encoding similar proteins), similar transcriptional 
profile (genes with the same expression in various tissues), similar 
protein function (GO description), or interaction of the encoded 
proteins (genes encoding interacting proteins). Systems biology, 
by integrating heterogeneous datasets such as expression data, 
sequence information, functional annotation, and the biomedical 
literature, allows reconstruction of gene networks and molecular 
pathways relevant for the different physiological and pathological 
conditions and accelerates the interpretation of monogenic as well 
as complex neurodevelopmental conditions67.
Very recently, software packages like Exomizer68, PhenIX69, and 
OVA70 have been made available that also incorporate phenotypic 
information in the prioritization process, significantly increasing 
its efficiency71. This extra layer of information, directly related to 
the specific disease affecting the patient(s), can be added to the 
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bioinformatics analysis pipeline thanks to the terminology stand-
ardization efforts of the Human Phenotype Ontology project55.
Finally, given the association between some human diseases and 
non-coding RNAs72, it is important to keep in mind the possible 
role of non-coding RNAs in the pathogenesis of ID, as suggested 
by the analysis performed by Gudenas and Wang73 on long non-
coding RNAs and CNVs in ID patients. In fact, pathogenic muta-
tions in RNAs that do not code for proteins shall not be detected by 
WES and may also be missed by WGS, depending on the quality of 
sequence annotation.
Transcriptional profiles, Brain ratio, and Fetal Brain ratio
Probably one of the most relevant factors determining the relevance 
of a specific gene in causing a given phenotype is its transcriptional 
profile. When manually inspecting the results of WES/WGS experi-
ments, immediately after scoring for the effect of identified variants 
on protein sequence, researchers ask about the expression of the 
candidate gene in the relevant tissue (e.g. brain for the ID phenotype). 
A number of databases collect mRNA expression data of multiple 
experiments (for example, the Gene Expression Omnibus [GEO] 
database, which is available at http://www.ncbi.nlm.nih.gov/geo/). 
A user-friendly gene expression portal is BioGPS (available at 
http://biogps.org/), initially established by the Genomics Institute 
of the Novartis Research Foundation74,75. Five reference datasets 
can be visualized with BioGPS, but the most reliable human dataset 
(GEO dataset GSE1133) explores 79 human tissues—including 21 
from the central nervous system (CNS)—and was obtained in 2004 
with the Affymetrix U133A arrays76.
We decided to reanalyze the transcriptional profile of 30 brain 
areas and 49 other tissues of the human body (all in triplicate) that 
were explored with the Affymetrix U133 Plus 2.0 (a more recent 
chip with more identified transcripts) by Neurocrine (GEO dataset 
GSE7307 entitled “Human body index - transcriptional profiling”). 
Part of this dataset (comprising 20 CNS areas) has been reported by 
Roth et al.77 (2006), but the complete dataset is more comprehen-
sive and gives the opportunity to visualize the transcriptional profile 
of 20,588 annotated genes and to compare the CNS and the rest of 
the body. In our analysis, we used the Neurocrine dataset to priori-
tize all available protein-coding genes on the basis of their relative 
expression level in the brain78. In fact, since the absolute expres-
sion value of a given transcript varies considerably compared with 
others, we first calculated an average level of expression in both 
CNS and non-CNS tissues for each available transcript and then we 
derived a “Brain ratio” (BR) defined as the average expression in 
(adult) CNS divided by the average expression in all other tissues. 
Such a ratio allows an easy and efficient comparison between genes 
with different “absolute” levels of transcription, highlighting those 
that are relatively more expressed in brain and therefore presumably 
more important for CNS function (and presumably cognition). We 
then ranked all 20,588 annotated genes by decreasing BR and found 
that approximately 8% of all protein-coding genes have a BR above 
2 but that approximately 10% of the 818 ID genes and approxi-
mately 25% of all XLID genes have a BR above 278. Supplementary 
Table 5 reports the list of the 84 ID genes with a BR of more than 2 
(plus two more genes immediately following in the ranking in posi-
tions 85 and 86) and their corresponding calculated BRs as well as 
the functional clustering and annotation obtained with DAVID and 
the list of GO terms used for REViGO. Finally, we also calculated 
a “Fetal Brain ratio” (fBR) (expression in fetal brain divided by 
average expression in adult CNS), and the list of 64 (out of the 818) 
ID genes with an fBR above 2 is reported in Supplementary Table 6 
along with the results of the DAVID analysis.
Careful inspection of Supplementary Table 5a suggests that genes 
with a high BR are usually mutated in nonsyndromic (“pure”) 
forms of ID but that ID genes with a lower BR (being more ubiq-
uitously expressed) associate with syndromic ID conditions. 
Similarly, examination of Supplementary Table 6a suggests that 
genes with a high fBR are sometimes mutated in brain malforma-
tions, consistent with their developmental function78. Figure 6 and 
Figure 7 visually illustrate the above-mentioned concepts thanks to 
the REViGO analysis of GO terms, and the comparison of the two 
figures is important: whereas REViGO analysis of all 818 ID genes 
showed a patchwork of very different Biological Process (Figure 6a) 
GO terms, Figure 7a (based on the 84 ID genes with a BR of more 
than 2) clearly points to cell-cell signaling, synaptic function, and 
transmission of the nervous impulse and Figure 7b (based on the 
64 ID genes with an fBR of more than 2) has 50% of GO terms 
pointing to regulation of transcription and the other 50% pointing 
to cell movements and developmental patterning. These differences 
are also apparent when g:Profiler is used to analyze the GO terms 
over-represented in these two lists (see Supplementary Table 7).
Conclusions
To date, more than 800 genes are known to be involved in the 
pathogenesis of syndromic and nonsyndromic conditions with ID 
(see Supplementary Table 2), and the functions of their respective 
proteins are very different. Since 800 out of ~4500 human disease 
genes currently listed in OMIM is ~18%, if we suppose that the 
same proportion of all human genes (~20,000) is related to ID, 
this would suggest that up to 3500 human genes (when mutated) 
could cause a Mendelian condition that includes ID as one of its 
components. However, this could be an overestimation since many 
human morbid genes currently reported by OMIM might have been 
identified also thanks to their ID phenotype: a more conservative 
estimate, based on the proportion of 10.5% of all protein-coding 
genes on the X involved in ID (Figure 5) that could be extended to 
the autosomes, leads to an estimate of approximately 2000 genes 
that, if mutated, would cause syndromic or nonsyndromic ID. 
Mutations in some of these genes might actually prove lethal during 
Page 11 of 16
F1000Research 2016, 5(F1000 Faculty Rev):599 Last updated: 25 DEC 2016
Figure 7. REViGO tree analysis of over-represented Gene Ontology (GO) terms obtained with DAVID. Panel (a) shows GO (Biological 
Process) terms associated with the 86 intellectual disability (ID) genes with a Brain ratio of 2 or more, while panel (b) shows GO (Biological 
Process) terms associated with the 64 ID genes with a Fetal Brain ratio of 2 or more. DAVID, Database for Annotation, Visualization, and 
Integrated Discovery; REViGO, Reduce + Visualize Gene Ontology.
a
b
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embryogenesis, but thanks to the new powerful sequencing 
techniques and more sophisticated bioinformatics pipelines, we 
might eventually identify all remaining protein-coding ID genes.
In any case, analysis of a gene’s transcriptional profile will be useful 
for the prioritization of candidate genes, and their relative expres-
sion in the adult or fetal CNS, estimated with the BR (or fBR), 
will facilitate comparison among genes with very different abso-
lute levels of transcription. We have to remember that, although we 
expect that most genes with a high BR (e.g. above 2) will mainly 
impair cognition whenever mutated, the majority of ID genes are 
also expressed in many other tissues (i.e. have a low BR) and will 
usually have a syndromic clinical presentation.
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